Close Menu

Carl Icahn is taking another swing at Genzyme; he is going after four seats on Genzyme’s nine-member board — for himself and for three associates, reports the New York Times. Icahn has not said what his plans might be for Genzyme, though the Times notes that when Icahn wins seats on boards, chief executive officers tend to leave and Genzyme’s Henri Termeer isn’t expected to go without a fight. “I’m sure Henri will fight,” says former Genzyme director Constantine Anagnostopoulos.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.